Synthesis of 1,2-benzisothiazolyloxypropanolamine derivatives and investigation of their activity at β-adrenoceptors
| Autor: | Giovanni Morini, Enzo Poli, Cristina Pozzoli, Alessandro Menozzi, Mara Comini |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Chronotropic
Adrenergic receptor Stereochemistry Adrenergic beta-Antagonists Pharmaceutical Science Propranolol In Vitro Techniques Structure-Activity Relationship Isoprenaline Drug Discovery medicine Animals Dose-Response Relationship Drug Molecular Structure Chemistry Muscle Smooth Adrenergic beta-Agonists Small intestine Rats Thiazoles medicine.anatomical_structure Bupranolol Specific activity Intracellular Muscle Contraction medicine.drug |
| Zdroj: | Il Farmaco. 60:810-817 |
| ISSN: | 0014-827X |
| DOI: | 10.1016/j.farmac.2005.07.008 |
| Popis: | The synthesis of 3-methoxy-1,2-benzisothiazole derivatives, substituted in position 5- (compounds 1-7) or 7- (compounds 8-14), with oxypropanolaminic side chains and the pharmacological investigation on their activity at beta-adrenoceptors are described. Compounds were prepared in an attempt to explore the ability of the benzisothiazole ring to interact with the beta-adrenoceptor site and to establish whether oxypropanolaminic derivatives recognise the beta3-adrenoceptor subtype. All the products were tested on rat atria, bladder and small intestine, which preferentially (but not exclusively) express beta1-, beta2- and beta3-adrenoceptors, respectively. When compared with the reference, non-specific, beta-adrenoceptor agonist isoprenaline, the products tested did not show any consistent beta-adrenoceptor agonistic activity in the different models. Most compounds relaxed smooth muscle preparations, but such effect was resistant to the blockade by propranolol (1 micromol/l), ICI 118,551 (1 micromol/l) or bupranolol (1-10 micromol/l), thus excluding that the spasmolytic effect involves any beta-adrenoceptors. When tested as antagonists, some of these products showed a concentration-dependent attenuation of the isoprenaline-induced effects in rat atria, without affecting beta-adrenoceptor-mediated relaxation in smooth muscle. These data confirm the ability of the benzisothiazole ring to interact with beta-adrenoceptors, but the substitution in 5- or 7-positions with oxypropanolaminic groups does not generate compounds endowed with specific activity at beta3-adrenoceptors. Conversely, most of these compounds behave as (specific) antagonists at beta1- (cardiac) adrenoceptors. At the maximum concentrations tested (1-100 micromol/l), these compounds also exert direct spasmolytic and negative chronotropic effects, which could be related to a blockade of Ca2+-dependent mechanisms at an intracellular level and/or an anaesthetic-like activity at plasma membranes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect